February 20-22, 2018
Boston, USA
Speakers
Expand/Collapse
Alexandre Akoulitchev
Chief Scientific Officer and Co-Founder
Oxford BioDynamics
Day Two
Thursday, February 22nd, 2018
13.30 | Multi-Center Biomarker Development for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
14.30 | Session Q&A; Panel
Thomas Skøt Jensen
CEO & Co-founder
Intomics
Day Two
Thursday, February 22nd, 2018
09.10 | Precision Medicine in a Data-rich Era – Challenges and Successful Bioinformatics Approaches
09.30 | Session Q&A; Panel
Speaker to be Confirmed
Cerveau Technologies
Day Two
Thursday, February 22nd, 2018
11.40 | Presentation to Be Confirmed
12.00 | Session Q&A; Panel
Alice Zhang
CEO
Verge Genomics
Brad Margus
Co-founder & CEO
Cerevance
Brendon Boot
Medical Director
Voyager Therapeutics
Damian Crowther
Director, R&D; Neuroscience IMED Biotech Unit
AstraZeneca
Day One
Wednesday, February 21, 2018
09.50 | Session Q&A; Panel
09.10 | Shedding Light on the Role of TREM2 in Alzheimer’s Disease
Douglas Bonhaus
CSO
Neuropore Therapeutics
Day Two
Thursday, February 22nd, 2018
16.20 | Session Q&A; Panel
16.00 | Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease
Douglas Galasko
Professor, Department of Neurosciences
University of California, San Diego
Day Two
Thursday, February 22nd, 2018
14.30 | Session Q&A; Panel
14.10 | Biomarker Data in Cerebrospinal Fluid in Parkinson’s Disease: The PPMI Study
Holly Soares
Head Translational Neuroscience
AbbVie
Day Two
Thursday, February 22nd, 2018
14.30 | Session Q&A; Panel
13.50 | Utility of Neurofilament Light Chain as a Translational Tool in Neurodegenerative Disorders
Jan Torleif Pedersen
Director, TBL Alzheimers Disease and Dementia
Neurodegeneration, H. Lundbeck A/S
Day Two
Thursday, February 22nd, 2018
09.30 | Session Q&A; Panel
08.50 | Development of Phospo-Tau Antibodies Targeting Pathologic Forms of Tau
Jay Schneider
Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit
Thomas Jefferson University
Day One
Wednesday, February 21, 2018
16.00 | Evaluating Translatability: Relevance of Rodent & Nonhuman Primate Preclinical Models of Cognitive Impairment to Clinical Drug Development
16.40 | Session Q&A; Panel
Johan Luthman
Vice President, Neuroscience Business Group
Eisai Pharmaceuticals
Day Two
Thursday, February 22nd, 2018
12.00 | Session Q&A; Panel
11.00 | Perspectives on Biomarker Applications Through Drug Development
Jonathan Brotchie
Co-Founder and Chairman
Atuka Inc.
Day One
Wednesday, February 21, 2018
16.40 | Session Q&A; Panel
16.20 | Translational Value of Non-Human Primate Models of Motor Impairment and Disease Progression in Parkinson’s Disease
Jonathan Levenson
Senior Director, Preclinical Research & Development
Proclara Biosciences
Day Two
Thursday, February 22nd, 2018
16.20 | Session Q&A; Panel
15.20 | Developing Preclinical Biomarkers of Proteopathic Seeds in Neurodegenerative Disease
Krzysztof Wicher
Principal Scientist and Group Leader
Ossianix
Larry Brown
Executive Vice President R&D;, Chief Scientific Officer
Noveome Biotherapeutics
Martin Tolar
Founder, President & CEO
Alzheon, Inc
Day Two
Thursday, February 22nd, 2018
09.30 | Session Q&A; Panel
08.30 | The Amyloid Cascade Hypothesis: The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease
Massimiliano Bianchi
General Manager & Scientific Director
Transpharmation Ltd
Day One
Wednesday, February 21, 2018
09.50 | Session Q&A; Panel
09.30 | The Importance of Microtubular Proteins & Cytokines in Neuroplasticity & Neuroinflammation
Ottavio Vitolo
VP Clinical Development
Homology Medicines Inc
Workshop A
Tuesday, February 20
08.00 | Exploring the Application of Gene Editing in the Treatment of CNS Disorders
Patrice Garnier
CEO
Amabiotics
Workshop C
Tuesday, February 20
15.00 | The Gut-Brain Axis: The Microbiome as a Versatile Target for Neurodegenerative Disease
Richard Ransohoff
Previously VP & Senior Research Fellow Neuroimmunology (Biogen)
Harvard Medical School
Day One
Wednesday, February 21, 2018
09.50 | Session Q&A; Panel
08.30 | (Re) Introduction to Microglia as Intrinsic Brain Cells
Richard Wade-Martins
Professor Molecular Neuroscience
University of Oxford
Robert Bell
Associate Research Fellow, Translational Gene Therapy
Pfizer
S. Pablo Sardi
R&D; Director
Sanofi-Genzyme
Day Two
Thursday, February 22nd, 2018
16.20 | Session Q&A; Panel
15.40 | The Role of GBA in Lysosomal Function, Neuroprotection and Progression in Parkinson’s Disease
Samuel Hasson
Principal Investigator, Neuroscience
Pfizer
Workshop B
Tuesday, February 20
11.30 | The Promise & Challenge of Neuroimmune Therapeutics: Targets, Models, and the Science Behind the Innate Immune System’s Role in Neurodegenerative Disease
Susan Browne
Director
Teva Pharmaceuticals
Tamara Maes
CSO and VP
Oryzon Genomics S.A
Tarek Samad
Head, Neurodegeneration
Pfizer
Day One
Wednesday, February 21, 2018
09.50 | Session Q&A; Panel
08.50 | Targeting Innate and Adaptive Immune Mechanisms to Modulate Neurodegeneration
Ping Chiao
Senior Director
Biogen
Day Two
Thursday, February 22nd, 2018
12.00 | Session Q&A; Panel
11.20 | Amyloid PET Imaging in Aducanumab Ph1b PRIME study
This website uses cookies to enhance your user experience. By using this site, you agree that we may store and access cookies on your device. For more details, please read our Cookie Policy.Ok
